ESMO 2022 | AMEERA-3: amcenestrant does not improve PFS in ER+/HER2- breast cancer

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, provides an overview of the Phase II AMEERA-3 trial (NCT04059484), which investigated the safety and efficacy of amcenestrant in patients with ER+/HER2- breast cancer. Patients either received amcenestrant or a control treatment consisting of either fulvestrant, aromatase inhibitors, or an estrogen receptor. The primary endpoint, progression-free survival (PFS), was not met, which is concordant with results from the Phase III AMEERA-5 trial (NCT04478266) of aromatase and palbociclib. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.